Glucose Control
Today’s insulin formulations save lives, but achieving tight control over blood-glucose levels remains a daily challenge for those living with type 1 diabetes (T1D). The JDRF Glucose Control Program is committed to making the management of T1D much better and safer through groundbreaking research and clinical trials that aim to develop new ways to help people keep their blood-sugar levels within a healthy range.
Our Approach
Insulin therapy must be calculated carefully, based on food intake, exercise, stress, illness and other (often unpredictable) factors. As a result, people with T1D spend an average of 10 hours a day with blood-sugar levels outside the recommended range, putting them at risk for dangerous high- and low-blood-sugar episodes.
-
![]()
Create next-generation insulins
-
![]()
Discover combination therapies
-
![]()
Prevent dangerous lows
Many Paths, One Purpose
Our research into glucose control technologies is just one potential pathway to finding a cure for T1D. Explore JDRF’s ambitious research portfolio.
All ResearchGet involved and help lead us toward a cure
Glucose Control Progress
2018
Hypoglycemia questions Hypo-RESOLVE aims to answer
JDRF joins an international consortium of 23 public and private organizations aiming to better understand hypoglycemia, or low blood sugar, and its impact on people with T1D.
2018
JDRF and Gubra join forces
JDRF and Gubra announce a partnership to develop glucose-responsive insulin (GRI), a form of insulin designed to work when blood glucose levels rise above healthy levels and to be inactive when blood glucose levels are in or below the standard range.
2018
ADA’s Scientific Sessions: It’s not just for type 2 anymore
SGLT inhibition had been approved for type 2 diabetes—and not T1D—but that’s about to change. Dapagliflozin (Farxiga®/Forxiga®) and sotagliflozin (Zynquista™) are submitted for approval for T1D, to be used in addition to insulin therapy to improve glucose control.
2019
FDA Approves Xeris Pharmaceuticals’ Glucagon to Treat Severe Hypoglycemia
The T1D community got a helping hand in their ability to avoid severe hypoglycemia when the FDA approved the first pre-mixed, pre-filled liquid glucagon formulation that can be used with either a pre-filled syringe or an auto-injector.
Looking Ahead
In the last decade, more than $45 million has been invested by JDRF in glucose control research. One day, thanks to improved insulin formulations and other drugs, staying within ideal blood-sugar range is no longer a challenge.